Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor

被引:57
作者
Schwarzenberger, P
Spence, SE
Gooya, JM
Michiel, D
Curiel, DT
Ruscetti, FW
Keller, JR
机构
[1] NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, LAB LEUKOCYTE BIOL, FREDERICK, MD 21702 USA
[2] NCI, FREDERICK CANC RES & DEV CTR, SAIC FREDERICK, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA
[3] UNIV ALABAMA, GENE THERAPY PROGRAM, BIRMINGHAM, AL USA
关键词
D O I
10.1182/blood.V87.2.472.bloodjournal872472
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this report, we describe a novel gene therapy approach for hematopoietic stem/progenitor cells using a specific receptor-mediated gene transfection procedure to target c-kit(+) cell lines. The vector consists of plasmid DNA containing a luciferase reporter gene that is condensed by electrostatic forces with polylysine (PL) covalently linked to streptavidin (binds biotinylated ligand) and PL covalently linked to adenovirus (AD; to achieve endosomal lysis) with the final addition of biotinylated steel factor (SLF-biotin). Targeted transfection of growth factor-dependent hematopoietic progenitor cell lines that express c-kit showed specific luciferase gene expression over cell lines that did not express c-kit. This effect was dependent on the dose of SLF-biotin and was competed by excess SLF or with monoclonal antibodies that recognize c-kit and block the binding of SLF to its receptor. Maximum transfection efficiency (>90%) requires a 2-hour incubation period of the vector with the cells, and maximum gene expression occurred 30 hours later. Removal of the endosomalytic agent, AD, from the vector resulted in the loss of gene expression. Vector targeting was versatile and could be changed by the addition of other biotinylated ligands. In principle, this vector should be broadly applicable to deliver genes to hematopoietic stem/progenitor cells in vitro and in vivo. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:472 / 478
页数:7
相关论文
共 30 条
[1]   GENE-THERAPY - CURRENT STATUS AND FUTURE-DIRECTIONS [J].
APPERLEY, JF ;
WILLIAMS, DA .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 75 (02) :148-155
[2]   SELECTIVE GROWTH-RESPONSE TO IL-3 OF A HUMAN-LEUKEMIC CELL-LINE WITH MEGAKARYOBLASTIC FEATURES [J].
AVANZI, GC ;
LISTA, P ;
GIOVINAZZO, B ;
MINIERO, R ;
SAGLIO, G ;
BENETTON, G ;
CODA, R ;
CATTORETTI, G ;
PEGORARO, L .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (03) :359-366
[3]   M-07E HUMAN LEUKEMIC FACTOR-DEPENDENT CELL-LINE PROVIDES A RAPID AND SENSITIVE BIOASSAY FOR THE HUMAN CYTOKINES GM-CSF AND IL-3 [J].
AVANZI, GC ;
BRIZZI, MF ;
GIANNOTTI, J ;
CIARLETTA, A ;
YANG, YC ;
PEGORARO, L ;
CLARK, SC .
JOURNAL OF CELLULAR PHYSIOLOGY, 1990, 145 (03) :458-464
[4]   GENE-THERAPY - INTRACELLULAR IMMUNIZATION [J].
BALTIMORE, D .
NATURE, 1988, 335 (6189) :395-396
[5]   ANTIGEN CD34+ MARROW-CELLS ENGRAFT LETHALLY IRRADIATED BABOONS [J].
BERENSON, RJ ;
ANDREWS, RG ;
BENSINGER, WI ;
KALAMASZ, D ;
KNITTER, G ;
BUCKNER, CD ;
BERNSTEIN, ID .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (03) :951-955
[6]  
BERENSON RJ, 1991, BLOOD, V77, P1717
[7]   GENE MARKING TO DETERMINE WHETHER AUTOLOGOUS MARROW INFUSION RESTORES LONG-TERM HEMATOPOIESIS IN CANCER-PATIENTS [J].
BRENNER, MK ;
RILL, DR ;
HOLLADAY, MS ;
HESLOP, HE ;
MOEN, RC ;
BUSCHLE, M ;
KRANCE, RA ;
SANTANA, VM ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 342 (8880) :1134-1137
[8]  
BRIDDELL RA, 1992, BLOOD, V79, P3159
[9]   HIGH-EFFICIENCY RECEPTOR-MEDIATED DELIVERY OF SMALL AND LARGE (48 KILOBASE GENE CONSTRUCTS USING THE ENDOSOME-DISRUPTION ACTIVITY OF DEFECTIVE OR CHEMICALLY INACTIVATED ADENOVIRUS PARTICLES [J].
COTTEN, M ;
WAGNER, E ;
ZATLOUKAL, K ;
PHILLIPS, S ;
CURIEL, DT ;
BIRNSTIEL, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (13) :6094-6098
[10]   ADENOVIRUS ENHANCEMENT OF TRANSFERRIN POLYLYSINE-MEDIATED GENE DELIVERY [J].
CURIEL, DT ;
AGARWAL, S ;
WAGNER, E ;
COTTEN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8850-8854